National Institute of Allergy and Infectious Diseases
  National Institutes of Health
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

About NIAID
 Overview
 Organization
  Organizational Charts
  Office of the Director
  DAIDS
   CIPRA
  DAIT
  DCR
  DEA
  DIR
  DMID
  VRC
 Director's Page
 Working at NIAID
 Finding People
 Visitor Information


Division of Acquired Immunodeficiency Syndrome (DAIDS)

Office for Policy in Clinical Research Operations (OPCRO)

The DAIDS Office for Policy in Clinical Research Operations (OPCRO) manages and supports the DAIDS clinical research and helps ensure compliance with applicable regulations, standards, and good clinical practice guidelines; study participant safety and welfare; and study quality and integrity. OPCRO, which includes the Clinical Research Resources Branch, Human Subjects Protection Branch, Policy, Training, and Quality Assurance Branch, Regulatory Affairs Branch, Pharmaceutical Affairs Branch; Clinical Trials Agreements Team, and Safety and Pharmacovigilance Team, carries out the following key functions:

  • Develops and maintains Division-wide clinical research polices and standard procedures and coordinates related training and quality assurance activities
  • Manages a portfolio of DAIDS contracts for independent site monitoring
  • Implements the DAIDS safety monitoring and reporting, related safety standards, and pharmacovigilance capacity
  • Manages Investigational New Drug Applications
  • Provides pharmaceutical expertise
  • Develops Clinical Trial Agreements
  • Protects the rights and well-being of clinical research subjects

back to top


Highlights

Dr. Carl Dieffenbach Appointed Director of the NIAID Division of AIDS
Feb. 1, 2008

News Releases

NIAID Creates HIV Vaccine Discovery Branch to Promote Synergy between Basic HIV Researchers and Vaccine Designers
June 25, 2008

NIAID Media Availability: Dr. Anthony S. Fauci to Address the United Nations on HIV/AIDS on June 10
June 5, 2008

Bulletin: Monitoring Board Recommends Stopping Experimental Treatment Regimen in International Study of Patients New to HIV Treatment
May 27, 2008

Special Announcements

Status of NIAID Adenovirus-based Vaccine Studies

Considerations for HIV Vaccine Clinical Trials in Adolescents

Guidance regarding HIV anti-retroviral treatment in developing countries

Search in About NIAID
 
E-mail Icon E-mail this page
Print Icon Print this page
Plug-ins and Viewers
To open PDFs on this page, download and install the Adobe Acrobat Reader.

Highlights

Dr. Carl Dieffenbach Appointed Director of the NIAID Division of AIDS
Feb. 1, 2008

News Releases

NIAID Creates HIV Vaccine Discovery Branch to Promote Synergy between Basic HIV Researchers and Vaccine Designers
June 25, 2008

NIAID Media Availability: Dr. Anthony S. Fauci to Address the United Nations on HIV/AIDS on June 10
June 5, 2008

Bulletin: Monitoring Board Recommends Stopping Experimental Treatment Regimen in International Study of Patients New to HIV Treatment
May 27, 2008

Special Announcements

Status of NIAID Adenovirus-based Vaccine Studies

Considerations for HIV Vaccine Clinical Trials in Adolescents

Guidance regarding HIV anti-retroviral treatment in developing countries